| __timestamp | Agios Pharmaceuticals, Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 44426000 |
| Thursday, January 1, 2015 | 141827000 | 46398000 |
| Friday, January 1, 2016 | 220163000 | 59897000 |
| Sunday, January 1, 2017 | 292681000 | 90296000 |
| Monday, January 1, 2018 | 1397000 | 89135000 |
| Tuesday, January 1, 2019 | 1317000 | 86125000 |
| Wednesday, January 1, 2020 | 2805000 | 96951000 |
| Friday, January 1, 2021 | 18777000 | 159938000 |
| Saturday, January 1, 2022 | 1704000 | 240813000 |
| Sunday, January 1, 2023 | 9504000 | 330123000 |
| Monday, January 1, 2024 | 4165000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Cytokinetics, Incorporated and Agios Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Cytokinetics has seen a remarkable increase in its cost of revenue, growing by approximately 643%, from $44 million to $330 million. This surge reflects the company's expanding operations and investment in research and development. In contrast, Agios Pharmaceuticals experienced a more volatile trajectory. After peaking in 2017, with costs reaching $293 million, Agios saw a dramatic decline, with costs plummeting by over 96% by 2022. This fluctuation may indicate strategic shifts or changes in operational focus. These trends offer a window into the financial strategies and market positioning of these biotech giants.
Cost of Revenue Trends: Pfizer Inc. vs Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Viatris Inc. and Cytokinetics, Incorporated
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and Cytokinetics, Incorporated
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Cytokinetics, Incorporated
Grifols, S.A. vs Cytokinetics, Incorporated: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Cytokinetics, Incorporated and Amphastar Pharmaceuticals, Inc.'s Expenses
Cytokinetics, Incorporated vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Perrigo Company plc and Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.